GLP1R and type 2 diabetes mellitus: In the DARWIN-T2D study, treatment with DPG for 6 months significantly reduced the albumin excretion rate (P = 0.045) compared with that in the control group (glucagon-like peptide 1 receptor agonist [GLP-1 agonist], dipeptidyl peptidase 4 inhibitor [DPP-4i] or gliclazide) but resulted in no difference in eGFR changes (P = 0.35) [14].